Afrezza

Product manufactured by Mannkind Corporation

Application Nr Approved Date Route Status External Links
BLA022472 None Respiratory (Inhalation) None Google , Wikipedia , PubMed , DailyMed , Raw OpenFDA , ECHA , ToxNet , JECFA , FAO , 21 CFR

Indications and Purposes

1 Indications And Usage Afrezza ® Is A Rapid Acting Inhaled Insulin Indicated To Improve Glycemic Control In Adult Patients With Diabetes Mellitus. Afrezza ® Is A Rapid Acting Inhaled Insulin Indicated To Improve Glycemic Control In Adult Patients With Diabetes Mellitus. ( 1 ) Important Limitations Of Use: In Patients With Type 1 Diabetes, Must Use With A Long-Acting Insulin ( 1 ) Not Recommended For The Treatment Of Diabetic Ketoacidosis ( 1 ) Not Recommended In Patients Who Smoke ( 1 ) Limitations Of Use Afrezza Is Not A Substitute For Long-Acting Insulin. Afrezza Must Be Used In Combination With Long-Acting Insulin In Patients With Type 1 Diabetes Mellitus. Afrezza Is Not Recommended For The Treatment Of Diabetic Ketoacidosis [See Warning And Precautions (5.6) ]. The Safety And Efficacy Of Afrezza In Patients Who Smoke Have Not Been Established. The Use Of Afrezza Is Not Recommended In Patients Who Smoke Or Who Have Recently Stopped Smoking.

All Formulated Excipients (0 Total)

None

Active Ingredients ( 1 Total)

Name Structure ZINC ID(s)
1. Insulin Human

Comments